Este manuscrito buscou a identificação do perfil brasileiro de automedicação na pandemia de COVID-19 e a reunião de informações sociodemográficas relacionadas ao uso da automedicação. Para tanto, foi investigado o conceito que os participantes depreendem sobre a automedicação, além de examinar qual o tipo de medicamento utilizado por quem se automedicou e seus efeitos colaterais. Foi realizada uma pesquisa no período de 03 de agosto a 30 de setembro de 2020. Os participantes deveriam apresentar uma idade mínima de 18 anos. As amostras estavam centradas em quem residia no Brasil. A pesquisa incluiu pessoas da população em geral. A coleta de dados se deu através de um questionário online, pois no referido período, as entrevistas presenciais deveriam ser evitadas devido ao contínuo lockdown. Coletaram-se dados de 1000 participantes para esta pesquisa. Os medicamentos que prevaleceram são da classe das vitaminas e, em segundo lugar, a Ivermectina. Destacou-se a indicação de automedicação por familiares. Os maiores índices de efeitos colaterais registrados foram cólicas intestinais e mal-estar. A prática da automedicação no Brasil mostrou-se preocupante no período de pandemia provocado pela COVID-19. Sendo assim, é importante que a população esteja atenta e seja criteriosa acerca das fontes de informações que discorrem sobre os medicamentos, evitando assim decisões precipitadas que podem ser mais prejudiciais.
Zika virus (ZIKV) remains a pressing global health concern due to its association with congenital Zika syndrome and the current lack of approved antiviral therapies. In this study, we evaluated the antiviral activity of three novel thiazolidinedione derivatives, GQ-402, GQ-396, and ZKC-10, against ZIKV in vitro and investigated their potential molecular targets through in silico analysis. GQ-402 exhibited the highest antiviral potency, with an IC50 of 15.7 µM, while ZKC-10 achieved the most substantial reduction in viral RNA levels, as determined by RT-qPCR. Molecular docking studies identified GQ-396 as the top-ranked inhibitor of the NS2B-NS3 protease and NS5 RNA-dependent RNA polymerase, suggesting distinct mechanisms of action among the compounds. These findings highlight the therapeutic potential of thiazolidinedione derivatives and underscore the need for further investigation to develop effective treatments for ZIKV infection.
Dengue is the most prevalent arboviral disease in tropical and subtropical regions, with over 13 million cases recorded in the Americas in 2024. Despite its enormous public health impact, no specific antiviral therapy is currently approved for dengue virus (DENV). In this context, this narrative review critically analyses the principal molecular targets of DENV, including structural proteins (C, prM/M and E), nonstructural proteins (NS1–NS5) and host factors, with emphasis on the development of small‐molecule antivirals and an evaluation of their progress in pre‐clinical and clinical studies. The NS2B–NS3 protease complex and NS5 (both RdRp and MTase domains) remain the most extensively explored targets, owing to the availability of high‐resolution crystal structures and higher inter‐serotype conservation. NS4B has emerged as the most clinically advanced target. Among direct‐acting antivirals, AT‐752 was also discontinued due to low viraemia at enrolment, while NITD‐688 remains among the most advanced pipeline molecules. Host‐directed therapies including anakinra and baricitinib are under clinical investigation for severe dengue. Key translational challenges include viral serotype diversity, pharmacokinetic limitations, cytotoxicity, and the timing of treatment initiation relative to viral kinetics. Advances in rational drug design, drug repurposing, allosteric inhibition, and targeted protein degradation (PROTACs) offer renewed perspectives for effective dengue therapeutics.